V

Virginia Clinical Research, Inc. | Norfolk, VA

Research site
(Unclaimed)
Location
6160 Kempsville Circle, 200A, Norfolk, Virginia, United States of America
Site insights

Top conditions

Psoriasis (17 trials)

Eczema (15 trials)

Dermatitis (15 trials)

Atopic Dermatitis (14 trials)

Acne Vulgaris (11 trials)

Top treatments

ASN002
Aminolevulinic Acid
Glycopyrronium
MT10109L
ALA
Dupilumab
BI 730357
Adapalene
PF-06700841
LY3009104

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

10 of 81
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color (ADmirable)

The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...

Enrolling
Atopic Dermatitis
Drug: Lebrikizumab

The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling
Hair Diseases
Alopecia
Drug: Baricitinib
Drug: Placebo

The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.

Enrolling
Plaque Psoriasis
Drug: LY3972406
Drug: Placebo

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab

This study is open to people with a skin disease called Netherton syndrome (NS). People can join the study if they are 12 years and older. The purpos...

Enrolling
Netherton Syndrome
Drug: Spesolimab - solution for infusion
Drug: Placebo matching to spesolimab - solution for infusion

This is a Phase 3 multicenter, double-blind study to evaluate the safety and efficacy of vehicle-controlled topical MOB015B in the treatment of Dista...

Active, not recruiting
Onychomycosis
Drug: Vehicle (Placebo Comparator)
Drug: MOB015B

A Phase 2b study looks at the safety and efficacy of a treatment that is being investigated for people with certain diseases. This study will be cond...

Enrolling
BCCs in Gorlin Syndrome Patients
Drug: Vehicle comparator
Drug: PTX-022

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) with the medication Ameluz® performed with the PDT-lamp BF-Rho...

Active, not recruiting
Superficial Basal Cell Carcinoma
Combination Product: Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product: Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)

Trial sponsors

Lilly logo

Lilly (9 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems